2bPrecise Releases V3.0 With Advanced Precision Oncology, Germline and Pharmacogenomic Capabilities

Key enhancements include point-of-care tools enabling oncologists to identify and act upon germline information uncovered during tumor profiling

PITTSBURGH, PA – July 23, 2020 – The latest update to the 2bPrecise precision health platform includes functionality to help oncologists identify genetic factors indicating patient risk for secondary cancers, as well as elevated risks for the patient’s family members.

Testing tumor tissue (somatic data) to assist in precise diagnoses and targeted treatments has been a standard of cancer care for years. However, these somatic results may also contain incidental information about mutations contained within the patient’s genetic profile. Presence of these complex mutations typically indicates a need for patients to undergo germline testing, not only to better understand their own cancer susceptibility but to uncover information about heritable variants that should be shared with biological relatives.

Since its development, the 2bPrecise platform has delivered somatic results into the oncology workflow, supporting clinical decision making to shorten the disease-burden timeline and improve outcomes. With the release of v3.0, 2bPrecise is bringing knowledge and NCCN- and ACMG-guidance into the workflow so oncologists will be able to refer patients to a genetic counselor for additional genomic testing when germline variants are found in the somatic results.

“This has been a genuine clinical challenge up until now,” said Joel Diamond, MD, chief medical officer at 2bPrecise. “Of course, oncologists are aware that germline mutations are contained in somatic results. But there has been no way to easily identify and understand the impact of these variants, consult current clinical guidelines to ascertain next-step recommendations, or close the loop by referring the patient for more testing. The enhancements we’ve made to the 2bPrecise precision oncology capabilities fill a critical gap in effective cancer care.”

An enterprise platform with software and tools spanning the care settings and specialties, 2bPrecise offers functionality and workflows beyond cancer care.  2bPrecise v3.0 introduces a single-click patient summary with a roll-up view of all genomic results available for the individual, minimizing clinical workflow disruption and averting alert fatigue. Deeper pharmacogenomics content and detailed result views enable deeper clinical decision support for providers treating pediatric patients, whose phenotype changes as they age past infancy. In addition, via integration with Allscripts dbMotion Agent Hub, the precision medicine platform now ingests clinical data from community sources, as well as the provider’s native EHR. Plus, 2bPrecise v3.0 adds breadth to its underlying knowledgebase architecture so the platform remains on the leading edge of advances in genomic science and associated clinical guidance.

Development of v3.0 capabilities occurred with direct input from 2bPrecise clients, according to CEO Assaf Halevy. “We are fortunate to work with many of the most innovative and intelligent leaders in health care. They have been generous in their advice and counsel, and candid in their feedback. This has allowed the 2bPrecise team to quickly ramp up new functionality that will help clinicians across all specialties use precision medicine to improve clinical practice and patient outcomes.”

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at www.2bPreciseHealth.com.

Media Contact
Erica Navar
Account Executive
Aria Marketing (for 2bPrecise)
(909) 538-9541
enavar@ariamarketing.com

Comments are closed.